Dyslipidemia, atherosclerosis and hypertension account for some of the largest patient populations in the world; therefore, many large pharmaceutical and biotech companies keep the study of these conditions spearheading their strategic plans. To provide options for studying these conditions and related targets, many rodent models have been developed.
Our Discovery Services group has extensive experience with mouse models of atherosclerosis (Apo E -/- and LDLR -/- mice) and the ability to perform the detailed necropsies and histological work needed to generate the complicated endpoints classically sought after from these studies. Additionally, rodent models of hyperlipidemia, like the Zucker Fatty rat, have been used time and again to examine the lipid-lowering effects of known standards of care.
The Golden Syrian hamster has been used for many years in the field of lipoprotein metabolism due to the presence of cholesteryl ester transfer protein, the key enzyme responsible in reverse cholesterol transport. The lipoprotein profile of hamsters, as well as their response to standard clinical therapies, is similar to that of human patients.
Charles River also offers the ZSF1 rat and telemetry-focused studies to examine potential effects of your candidate on a hypertensive model.
Whether you are looking for a primary in vivo screening model or a complicated mechanism of action study with your lead candidates, we have the experience to help you design a study in the appropriate model.